Auxilium receives USPTO patent for XIAFLEX product Auxilium Pharmaceuticals, Inc. , a specialty biopharmaceutical firm, today announced that america Patent and Trademark Workplace released U http://orlistatindia.com/xenical-generic-vs-brand.htm .S. Patent No. The patent’s independent promises recite a drug item, an activity for producing the medication item, and pharmaceutical formulations comprising the medication product. ‘We have been happy that XIAFLEX today has patent safety which we anticipate will expire in July 2028,’ stated Armando Anido, LEADER President and Officer of Auxilium Pharmaceuticals. ‘With one accepted indication for XIAFLEX, another in late-stage medical trials, and more potential indications in the offing, we think that extending our patent safety for another 18 years can be an important accomplishment.